Table 3 Patients’ characteristics in the two subgroups (2003–2009 vs 2010–2017).
From: Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy
Characteristics | 2003–2009 (N = 80, 23%) | 2010–2017 (N = 262, 77%) | p value |
|---|---|---|---|
Age (median, range) | 49 (26–79) | 49 (25–81) | 1.00 |
cT stage | |||
cT1 | 6 (7.5%) | 49 (18.7%) | < 0.001 |
cT2 | 28 (35%) | 140 (53.4%) | |
cT3-4 | 46 (57.5%) | 73 (27.9%) | |
ypT stage | |||
ypT0 | 9 (11.4%) | 98 (37.4%) | < 0.001 |
ypT1 | 26 (32.9%) | 81 (30.9%) | |
ypT2 | 22 (27.8%) | 53 (20.2%) | |
ypT3-4 | 22 (27.8%) | 30 (11.5%) | |
NA (not available) | 1 | ||
cN stage | |||
cN0 | 18 (23.4%) | 70 (27%) | 0.475 |
cN1-3 | 59 (76.6%) | 189 (73%) | |
NA | 3 | 3 | |
ypN stage | |||
ypN0 | 29 (38.7%) | 147 (63.4%) | < 0.001 |
ypN1-3 | 46 (61.3%) | 85 (36.6%) | |
NA | 5 | 30 | |
cM stage | |||
cM0 | 63 (80.8%) | 230 (88.1%) | 0.108 |
cM1 | 15 (19.2%) | 31 (11.9%) | |
NA | 2 | 1 | |
Histological grading | |||
G1/2 | 32 (47.1%) | 99 (39.4%) | 0.311 |
G3 | 36 (52.9%) | 152 (60.6%) | |
NA | 12 | 11 | |
Proliferation Index Ki67 | |||
Low (< 30%) | 19 (86.4%) | 91 (58.3%) | 0.028 |
High (≥ 30%) | 3 (13.6%) | 65 (41.7%) | |
NA | 58 | 106 | |
Pathologic complete response | |||
No | 72 (90%) | 167 (63.7%) | < 0.001 |
Yes | 8 (10%) | 95 (36.3%) | |
Subtype | |||
Luminal A | 23 (29.1%) | 52 (19.9%) | 0.069 |
Luminal B Her2+ | 14 (17.7%) | 58 (22.2%) | |
Luminal B Her2− | 15 (19.0%) | 29 (11.1%) | |
HER2+ | 13 (16.5%) | 47 (18.0%) | |
Triple negative | 14 (17.7%) | 76 (28.8%) | |
NA | 1 | ||
Chemotherapy | |||
HER2-R antibody therapy | 16 (20%) | 78 (29.9%) | < 0.001 |
Platinum | 1 (1.2%) | 62 (23.7%) | |
Others | 63 (78.8%) | 102 (39.1%) | |
Combination of antibody and platinum | 0 (0%) | 19 (7.3%) | |
NA | 1 |
